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Objectives. Insulin resistance is associated with in-
creased CD36 expression in a number of tissues.
Moreover, excessmacrophageCD36may initiateath-
erosclerotic lesions. The aim of this study was to
determine whether plasma soluble CD36 (sCD36)
wasassociatedwith insulin resistance, fatty liver and
carotidatherosclerosis innondiabeticsubjects.
Methods. In 1296 healthy subjects without diabetes or
hypertension recruited from 19 centres in 14 Euro-
pean countries (RISC study), we determined the lev-
els of sCD36, adiponectin, lipids and liver enzymes,
insulin sensitivity (M ⁄ I) by euglycaemic–hyperinsuli-
naemic clamp, carotid atherosclerosis as intima–
media thickness (IMT)and twoestimatesof fatty liver,
the fatty liver index (FLI) and liver fat percentage
(LF%).
Results. IMT, FLI, LF%, presence of the metabolic
syndrome, impaired glucose regulation, insulin and
triglycerides increased across sCD36 quartiles
(Q2–Q4), whereas adiponectin and M ⁄ I decreased
(P £ 0.01). sCD36 was lower in women than in men
(P = 0.045). Log sCD36 showed a bimodal distribu-
tion, and amongst subjects with sCD36 within the
log-normal distribution (log-normal population,
n = 1029), sCD36was increased in subjects with im-
paired glucose regulation (P = 0.045),metabolic syn-
drome (P = 0.006)or increased likelihoodof fatty liver
(P < 0.001). sCD36correlatedsignificantlywith insu-
lin, triglycerides,M ⁄ I and FLI (P < 0.05) after adjust-
ment for study centre, gender, age, glucose tolerance
status, smoking habits and alcohol consumption. In
the log-normal population, these relationships were
stronger than in the total studypopulationand,addi-
tionally, sCD36 was significantly associated with
LF%andIMT(P < 0.05).
Conclusions. In this cross-sectional studyof nondiabetic
subjects, sCD36 was significantly associated with
indices of insulin resistance, carotid atherosclerosis
and fatty liver. Prospective studies are needed to fur-
ther evaluate the role of sCD36 in the inter-relation-
ship between atherosclerosis, fatty liver and insulin
resistance.
Keywords: low-grade inflammation, metabolic
syndrome, nonalcoholic fatty liver disease, sCD36,
type2diabetes.
Abbreviations: sCD36, soluble CD36; MetSy, metabolic
syndrome; T2D, type 2 diabetes; CVD, cardiovascu-
lar disease; oxLDL, oxidized low-density lipoprotein;
BP, blood pressure; FPG, fasting plasma glucose;
FFM, fat-freemass;LDL, low-density lipoproteincho-
lesterol; HDL, high-density lipoprotein cholesterol;
FFA, free fatty acids; GGT, gamma-glutamyltransfer-
ase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; M ⁄ I, insulin sensitivity; FLI, fatty
liver index; MRS, magnetic resonance spectroscopy;
BMI, body mass index; LF%, liver fat percentage;*The RISC investigators details are listed in
Appendix.
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IMT, intima–media thickness; NGT, normal glucose
tolerance; IFG, impaired fasting glucose; IGT, im-
paired glucose tolerance; +MetSy, presence of the
metabolic syndrome; )MetSy, absence of the meta-
bolic syndrome; Log-normal population, subjects
withsCD36within the log-normaldistribution
Introduction
The metabolic syndrome (MetSy) describes a cluster
of factors, including obesity, that are associated
with an increased risk of type 2 diabetes (T2D) and
cardiovascular disease (CVD). In addition, fat accu-
mulation in the liver correlates with all components
of the MetSy and has been proposed to be a novel
component of the MetSy [1, 2]. From the public
health perspective, there is a strong incentive to
identify people at risk of future T2D and CVD. Thus,
it is important to identify and evaluate new biomar-
kers linked to the MetSy and to use these biomar-
kers to increase our understanding of its patho-
physiology.
CD36 is expressed in a variety of tissues and has
a number of tissue-specific functions [3–5]. CD36
on the surface of muscle, liver and fat tissue is in-
volved in uptake of fatty acids, and a number of
studies have indicated that there is a relation be-
tween elevated CD36 expression in these tissues
and insulin resistance [6–8]. CD36 on the surface
of macrophages may initiate foam cell formation
eventually leading to atherosclerotic lesions and
thus may be an important risk factor for CVD. The
process of foam cell formation is initiated and en-
hanced by the binding of oxidized low-density lipo-
protein (oxLDL) to CD36 receptors with subse-
quent accumulation of cholesterol in macrophages
[3–5]. In mice, increased liver CD36 expression in
response to diet-induced obesity was associated
with liver fat accumulation and insulin resistance
[6], and defective insulin signalling led to increa-
sed CD36 expression on macrophages in ob ⁄ob
mice [9]. Together, these results suggested impor-
tant correlations between decreased insulin sensi-
tivity, accumulation of ectopic fat, inflammation
and possible future atherosclerosis.
The recently identified soluble CD36 (sCD36) was
proposed to reflect tissue CD36 expression and
may thus be a potential marker integrating insulin
resistance and atherosclerosis [10]. Indeed, we
have reported consistent associations between
sCD36, obesity and insulin resistance in insulin-
insensitive conditions [10–13]. Elevated sCD36
was present in both overt T2D and prediabetic
conditions such as obesity and polycystic ovary
syndrome, indicating that sCD36 possesses the
potential to reflect early changes in CD36 expres-
sion involved in the pathogenesis of diabetes or
the development of components of the MetSy. The
purpose of this study was to evaluate the rela-
tionships between plasma sCD36 and measures
of insulin resistance, fatty liver and carotid ath-
erosclerosis in a large population of nondiabetic
healthy subjects.
Setting and methods
Study subjects
The RISC study is a prospective, observational, co-
hort study, anddetails of the rationaleandmethodol-
ogyhavebeenpublishedpreviously [14]. Inbrief, clin-
ically healthy Caucasian men and women, aged
between30and60 years,wererecruited from19cen-
tres in 14European countries. Initial exclusion crite-
ria were as follows: treatment for obesity, hyper-
tension, lipid disorders or diabetes; pregnancy;
cardiovascular or chronic lung disease; weight
change of ‡5 kg in the previous 6 months; cancer in
theprevious5 years; and renal failure.Exclusion cri-
teria after screening were as follows: systolic ⁄dia-
stolic blood pressure (BP) ‡140 ⁄90 mmHg; fasting
plasma glucose (FPG) ‡7.0 mmol L)1; 2-h plasma
glucose ‡11.0 mmol L)1; total serum cholesterol
‡7.8 mmol L)1; serum triglycerides ‡4.6 mmol L)1;
ECG abnormalities; and carotid artery plaques. This
study included 1296 subjects (712 women and 584
men) who satisfied all criteria, had available data for
plasma sCD36 level and for whom the clamp study
(see below) passed the quality control check. Local
ethics committee approval was obtained by each
recruitingcentre.
Physical examination and lifestyle factors
Height, body weight, percentage body fat, fat-free
mass (FFM), waist circumference, sitting BP and
heart rate were measured as previously described
[15]. A lifestyle questionnaire was used to collect
information about smoking habits and alcohol con-
sumption [14].
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Analytical determinations
Bloodcollectedduring the studieswasseparated into
plasma and serum, divided into aliquots and stored
until required formeasurement at)20 C for glucose
and at )80 C for lipids, insulin and sCD36. Plasma
levels of glucose and adiponectin and serum levels of
insulin, low-density lipoprotein cholesterol (LDL),
high-density lipoprotein cholesterol (HDL), triglyce-
rides, free fatty acids (FFAs), gamma-glutamyltrans-
ferase (GGT), aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) were all measured in
acentral laboratory, aspreviouslydescribed [15].
Plasma sCD36
sCD36 was measured using an in-house enzyme-
linked immunoassay (ELISA) in Li-heparin plasma
[10].ApoolofEDTAplasmawasapplied insevendilu-
tions and used to produce a standard concentration
curve. Internal controlswere run inquadruplicate on
each plate. Runs were accepted if the controls were
within ±2 SD frommean, andmostwerewithin1 SD.
The intra-assay coefficient of variation (CV) was 6%,
and total day-to-day assayCVwas16.4%. Log-trans-
formed standard curves were linear. A few measure-
ments were outside the standard curve range and
were calculated by extrapolation. sCD36 was mea-
sured in fasting samples. The detection limit, estab-
lished using absorbance of the zero calibrator plus
2 SD of the absorbance of the lowest calibrator
(n = 48),was0.027arbitraryunits in thisstudy.
Insulin clamp
A euglycaemic–hyperinsulinaemic clamp was per-
formed in all subjects as described previously [15].
Insulin sensitivity was expressed as the ratio of theM
value – averaged over the final 40 min of the 2-h
clamp and normalized with respect to FFM – to the
mean plasma insulin concentration (I) during the
same interval (M ⁄ I, in units of lmol min)1 kg
FFM)1.(nmol L)1))1).
Fatty liver index
The fatty liver index (FLI) is an algorithm based on
bodymass index (BMI),waist circumference, triglyce-
rides and GGT with an accuracy of 0.84 (95% confi-
dence interval, 0.81–0.87) indetecting fatty liver [16].
In the present study, we have used more restrictive
cut-off values forFLI (<20and>60), forwhichwehave
previously estimated the likelihood of having or not
having fatty liver using the Bayes’ theorem in the
RISC study cohort [1]; when the index value (FLI) is
>60, the likelihoodofhaving fatty liver is >78%, and if
FLI is <20, the likelihood of not having fatty liver is
>91%. Subjects were then categorized into three
groupsaccording to FLI: <20, 20–60and>60. Tovali-
date the use of FLI in the RISC cohort, we have evalu-
ated the hepatic fat content in a separate group of
subjects (n = 37) by magnetic resonance spectros-
copy (MRS) and compared the results with our esti-
mated cut-off points for the likelihood of having fatty
liver on the basis of FLI values. Subjects with FLI <20
had no hepatic fat content (range, 0.4–4.2%; n = 6),
whereas those with FLI >60 had steatosis with hepa-
tic fat content >5% (range, 8.6–24.0%;n = 10).More-
over, FLI was significantly correlated with hepatic fat
content determined by MRS (r = 0.61, P = 0.0001)
[17].
Liver fat percentage
Liver fat percentage (LF%) is an algorithm based on
thepresenceof theMetSyandT2DMaswell as fasting
insulin, AST and ALT to predict the degree of liver fat
accumulation.Thealgorithmwasdevelopedandvali-
dated using 1H-MRS, and moreover, the algortitm
was validated in a separate study group [18]. The R2
of theLF%algorithmagainst 1H-MRSwas0.49 [18].
Carotid intima–media thickness analysis
We followed a validated scanning and reading proto-
col forultrasoundmeasurementofcarotidartery inti-
ma–media thickness (IMT) [19] as previously de-
scribed [15]. The IMT value was computed as an
averageof all available carotidwalls (up to fourwalls).
Intra-observer variability of IMTmeasureswas tested
in 100 randomly chosen scans to calculate the aver-
age percentage difference between the first and sec-
ond reading relative to the first reading; themeandif-
ferencewas4.6 ± 3.0%.
Glucose tolerance and theMetSy
Participants underwent a 2-h standard75-g oral glu-
cose tolerance test and were classified into three
groups according to the American Diabetes Associa-
tion criteria (proposed in 2000): normal (NGT), im-
paired fasting glycaemia (IFG) and impaired glucose
tolerance (IGT). Subjects with IFG and ⁄or IGT were
grouped together and classified as impaired glucose
regulation (n = 182 or 14% of the total cohort). The
presence (+MetSy) or absence ()MetSy) of the MetSy
was defined according to the criteria of the Interna-
tionalDiabetesFederation [20].
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Statistical analysis
All data analyses were performed with spss 11.0 for
Windows (SPSS, Inc., Chicago, IL, USA). The results
for continuous variables are reported as the
mean ± SD unless otherwise stated and for class
variables as percentages. Variables with skewed dis-
tributions (sCD36, insulin, triglycerides, FFA, adipo-
nectin, ALT, GGT, FLI, LDH, HDL,M ⁄ I and IMT) were
logarithmically transformed for statistical analyses.
One-way anova and Tukey’s post hoc analysis were
used to analyse the markers of insulin resistance,
carotid atherosclerosis and fatty liver by quartiles
(Q1–Q4) of sCD36. Chi-square tests were used for bi-
nominal variables (MetSy and IGT ⁄ IFG). Partial cor-
relation analyses were used to test the relationship
between sCD36 and the same markers when ad-
justed for centre, gender, glucose tolerance status,
smoking habits and alcohol consumption. P £ 0.05
wasconsideredstatisticallysignificant.
Results
Effect of gender, glucose tolerance MetSy and FLI on sCD36
PlasmasCD36wassignificantly lower inwomenthan
inmen, similar to other indices of insulin resistance,
atherosclerosis and fatty liver, such as fasting glu-
cose, insulin, LDL, triglycerides, ALT,GGT,FLI, LF%,
BMI, waist circumference, clamp FFA, IMT, and dia-
stolic and systolic BP, whereas insulin sensitivity
(M ⁄ I), plasmaadiponectinandHDLwere significantly
higher (Table 1). Accordingly, the presence of the
MetSy,butnot IGT ⁄ IFG,was lower inwomen.Bycon-
trast (with respect to the direction of change in
parameters that have previously been associated
with insulin sensitivity), fasting FFAs, age and per-
centage body fat were significantly higher in women
than inmen.
Quartiles of plasma sCD36
HDL andM ⁄ I decreased across quartiles (Q2, Q3 and
Q4) of plasma log sCD36, whereas FPG, insulin, tri-
glycerides, LDL, clamp FFA, age, waist circumfer-
ence, percentage body fat, ALT, GGT, FLI, LF%, BMI,
systolic BP, IMT, IGT ⁄ IFG and +MetSy increased
across the same quartiles (anova; P < 0.01 for all)
(Table 2, Fig. 1). Plasma adiponectin decreased
acrossall four quartiles. For all theseparameters, the
largest difference was observed between Q2 and Q4
values of plasma sCD36, and for all variables, except
ALT, this difference was significant (Table 2). Most
variables exhibited a J-shaped (or inverse J-shaped)
relationshipwith sCD36,withQ1values showing the
opposite trend to that observed fromQ2 to Q4. Waist
circumference, percentage body fat, BMI, ALT, GGT,
LF%, +MetSy and IGT ⁄ IFG showed significant differ-
ences between Q1 and Q2 (Table 2, Fig. 1), whereas
LFI,M ⁄ I, IMT and the all other variables shown in Ta-
ble 2 did not reach statistical significance. In both
men and women, fasting insulin, waist circumfer-
ence, FLI, LF%, +MetSy and percentage body fat in-
creasedacross sex-specificquartiles (Q2,Q3andQ4)
of sCD36, whereas adiponectin decreased across all
four quartiles (anova; P < 0.05 for all; data not
shown). In women, significant differences across
quartiles of plasma sCD36 were seen for age, BMI,
fasting glucose, triglycerides, HDL, systolic BP and
IGT ⁄ IFG (P < 0.02 for all), whereas changes across
quartiles of sCD36were seen forGGT (P = 0.021) and
LDL (P = 0.005) inmen.
Bimodal distribution of sCD36: two populations
The J-shaped relationship between most variables
and quartiles of sCD36 suggested the possible exis-
tence of two populations of sCD36 values. Closer
examination of the log-transformed distribution of
sCD36 revealed that part of the total population had
extremely low values of sCD36 (Fig. 2). It was evident
that log values of sCD36 <)0.38 do not belong to the
log-normal distribution of sCD36. Excluding those
individuals with log sCD36 <)0.38, we observed sig-
nificantlyhigherplasmasCD36 levels in theresulting
log-normal population in men versus women (4.1 ±
3.5vs.3.7 ± 3.1;P = 0.001), insubjectswith IGT ⁄ IFG
versusNGT (4.5 ± 4.0 vs. 3.8 ± 3.2;P = 0.045)and in
subjects +MetSy versus )MetSy (4.6 ± 3.9 vs.
3.8 ± 3.2;P = 0.006).Thedifferences inglucose toler-
anceandMetSystatus (+MetSy ⁄)MetSy)were signifi-
cant in women (P < 0.05) but not in men. Moreover,
plasma sCD36 levels increased significantly with
increasing likelihood of fatty liver (FLI < 20 fi 20–
60 fi >60: 3.5 ± 3.1 vs. 4.2 ± 3.5 vs. 4.6 ± 3.4;
P < 0.001). After post hoc analysis, plasma sCD36
wassignificantly lower insubjectswithFLI < 20 than
in subjects with FLI 20–60 (P = 0.009) and FLI > 60
(P = 0.009).
We also investigated whether the characteristics of
the two populations of sCD36 distribution differed
from each other, but observed no differences in the
parameters shown in Table 1 except for significantly
higher levels of plasma adiponectin (9.00 ± 3.89 vs.
8.22 ± 3.70 mg L)1; P < 0.001), FFA clamp (0.062 ±
0.179 vs. 0.052 ± 0.084 mmol L)1; P < 0.028) and
increased +MetSy (18.3 ± 38.8 vs. 12.5 ± 33.1; P <
0.027) in the population with log sCD36 below )0.38
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(n = 267).Ofnote, thehigherplasmaadiponectin lev-
elswerenot causedbyahigher ratio ofwomen tomen
inthe twopopulations (P = 0.75).
Correlation analyses
In the total population, univariate analysis revealed
significant correlations between plasma sCD36 and
fasting insulin, triglycerides, adiponectin, clampFFA
andFLI (Table3).Theseassociationsremainedsignif-
icant after adjustment for centre, gender, age, glu-
cose tolerance status, smoking habits and alcohol
consumption using multivariate analysis. In addi-
tion, adjustment for these covariates introduced an
inverse relationship between M ⁄ I and sCD36. The
sCD36 log-normal population (log sCD36 ‡ )0.38)
revealed stronger or similar associations between
sCD36 and fasting insulin, adiponectin, triglyce-
rides, clampFFA, GGT and FLI, and significant asso-
ciations were introduced between sCD36 and fasting
glucose, LDL, HDL, +MetSy, LF% and carotid IMT
(Table 3). Except for fasting glucose, adiponectin and
+MetSy, these associations persisted after adjusting
for centre, gender, age, glucose tolerance status,
smokinghabitsandalcoholconsumption.Univariate
or multivariate analysis of sCD36 and the variables
shown in Table 3 within the population with log
sCD36 < )0.38 showed no significant associations.
A strong positive correlation between the two esti-
mates of fatty liver, FLI and LF%, was observed both
in the totalpopulation (r = 0.66;P < 0.001)and in the
sCD36 log-normalpopulation (r = 0.64;P < 0.001).
Discussion
In this cross-sectional study of nondiabetic healthy
subjects, plasma sCD36 showed significant associa-
tions with indices of insulin resistance, carotid
Table 1 Clinicaland laboratorycharacteristicsof theRISCcohort
All Male Female P-value
n (1276–1296) 1296 584 712
Age (years) 43.9 ± 8.3 43.2 ± 8.5 44.4 ± 8.1 0.010
Waist circumference (cm) 87 ± 13 93 ± 10 81 ± 12 <0.001
Percentagebody fat (%) 20.9 ± 8.8 19.0 ± 7.9 22.6 ± 9.1 <0.001
Bodymass index (kg m)2) 25.5 ± 4.0 26.4 ± 3.5 24.8 ± 4.3 <0.001
Diastolicbloodpressure (BP) (mmHg) 74 ± 8 76 ± 7 73 ± 8 <0.001
SystolicBP (mmHg) 117 ± 12 122 ± 11 114 ± 13 <0.001
Heart rate (beats min)1) 68 ± 10 66 ± 10 70 ± 10 <0.001
Low-density lipoproteincholesterol (mmol L)1)* 2.9 ± 0.8 3.1 ± 0.8 2.8 ± 0.8 <0.001
High-density lipoproteincholesterol (mmol L)1)* 1.4 ± 0.4 1.2 ± 0.3 1.6 ± 0.4 <0.001
Triglycerides (mmol L)1)* 1.1 ± 0.7 1.3 ± 0.9 0.9 ± 0.5 <0.001
Fasting free fattyacids (FFA) (mmol L)1)* 0.538 ± 0.228 0.474 ± 0.222 0.590 ± 0.219 <0.001
ClampFFA (mmol L)1)* 0.054 ± 0.110 0.063 ± 0.099 0.048 ± 0.118 <0.001
Fastingglucose (mmol L)1) 5.1 ± 0.5 5.2 ± 0.5 4.9 ± 0.5 <0.001
Fasting insulin (pmol L)1)* 32 ± 21 35 ± 25 30 ± 18 <0.001
Gamma-glutamyltransferase (U L)1)* 25.9 ± 19.0 32.9 ± 24.2 21.7 ± 20.3 <0.001
Alanineaminotransferase (U L)1)* 20.1 ± 11.6 24.8 ± 13.4 16.4 ± 8.1 <0.001
Fatty liver index* 27.8 ± 25.0 38.5 ± 25.0 18.9 ± 21.2 <0.001
Liver fatpercentage * 2.04 ± 1.44 2.47 ± 1.73 1.69 ± 1.04 <0.001
Plasmaadiponectin (mg L)1)* 8.4 ± 3.8 6.5 ± 2.6 9.9 ± 3.8 <0.001
M ⁄ I (lmol min)1 kgFFM)1 nmol L)1)* 141 ± 72 124 ± 64 155 ± 75 <0.001
Carotid intima–mediathickness (mm)* 0.60 ± 0.09 0.62 ± 0.09 0.59 ± 0.08 <0.001
+MetSy* 13.70 ± 34.40 18.58 ± 38.93 9.70 ± 29.62 <0.001
Impairedglucose tolerance ⁄ IGF 14.06 ± 34.78 15.44 ± 36.16 12.94 ± 33.59 0.20
PlasmaCD36* 3.1 ± 3.3 3.3 ± 3.5 2.9 ± 3.2 0.045
Valuesaremeans ± SD.*P-valuesbasedonstatisticalanalysesusing log-normalizedvalues.
A. Handberg et al. | sCD36 and cardiovascular risk factors
ª 2011 The Association for the Publication of the Journal of Internal Medicine Journal of Internal Medicine 5
atherosclerosis and fatty liver. The association be-
tween sCD36 and a large range of risk factors for
insulin resistance and CVD was consistently signifi-
cant. Closer inspection showed that these associa-
tions tended to be J-shaped (or inverse J-shaped) for
themajority of risk factors. Thus, both high and very
low sCD36 levels in a general healthy population
seem to carry an increased risk of disease. Several
studies have demonstrated an association between
highCD36expressionand increased foamcell forma-
tion and unstable atherosclerosis [3–5, 21, 22]. On
the other hand, two studies of the general phenotypic
appearance of CD36-deficient patients showed that
CD36 deficiency was associated with hyperlipida-
emia and an atherogenic lipid profile, insulin resis-
tance andmildhypertension [23,24]. Althoughcase–
control studies of larger cohorts of individuals with
CD36deficiencyarenecessary [25], itcouldbespecu-
lated that both toomuch and too little sCD36may be
associated with an increased disease risk, at least in
clinically healthy people. Low CD36 expression [26]
was associatedwith increased fatty acid flux to the li-
ver, which may result in dyslipidaemia and insulin
resistance. High sCD36 was associated with insulin
resistance [10,12,13],and indiabeticmouseandhu-
man monocytes, CD36 expression was upregulated
asaconsequenceof impaired insulinsignalling [9]. In
addition, impaired insulin signalling was associated
with elevated CD36 expression in circulating leuco-
cytes in a mouse model of increased atherosclerosis
risk [27]. Furthermore, high oxLDL, as a conse-
quence of increased oxidative stress and dyslipida-
emia, upregulates monocyte and macrophage CD36
expression andmay lead to accelerated development
of atherosclerosis [3, 5]. Therefore, our findings that
bothhighand lowsCD36maybeassociatedwith risk
factors for insulin resistance andCVDare not in con-
flict with previously published data. Other possible
explanations for our findings include a mutation in
the coding region of the CD36 gene, which could re-
sult in altered immunoreactivity with the antibodies
used in the sCD36 ELISA, and lead to falsely low
sCD36 levels. A CD36 promotor mutation in Cauca-
sianslinkedtodiabeteshasbeenreported,andmuta-
Table 2 Relationship between sCD36 and anthropometric measures and biochemicalmarkers of insulin resistance and fatty liver
in theRISCcohort
PlasmasCD36
Pall
Q1 Q2 Q3 Q4
<0.8 0.8–2.3 2.3–4.3 >4.3
323 325 325 323
Age (years) 43.3 ± 8.2* 43.4 ± 8.3* 43.2 ± 8.1* 45.4 ± 8.4 0.002
Waist circumference (cm) 86 ± 13** 83 ± 12*,*** 88 ± 12 89 ± 12 <0.001
Percentagebody fat (%) 21.7 ± 9.5** 19.4 ± 8.0* 20.6 ± 8.9 22.1 ± 8.5 <0.001
Bodymass index (kg m)2) 25.8 ± 4.4** 24.6 ± 3.7*,*** 25.5 ± 3.9 26.2 ± 4.0 <0.001
Diastolicbloodpressure (BP) (mmHg) 74 ± 8 74 ± 8 75 ± 8 75 ± 8 0.143
SystolicBP (mmHg) 117 ± 13 116 ± 12* 117 ± 13 119 ± 12 0.034
Heart rate (beats min)1) 67 ± 10 68 ± 11 69 ± 10 69 ± 10 0.085
Low-density lipoproteincholesterol (mmol L)1)a 2.9 ± 0.8* 2.8 ± 0.8* 2.9 ± 0.8* 3.1 ± 0.8 <0.001
High-density lipoproteincholesterol (mmol L)1)a 1.4 ± 0.4 1.5 ± 0.4*,*** 1.4 ± 0.4 1.4 ± 0.4 <0.001
Triglycerides (mmol L)1)a 1.1 ± 0.9* 1.0 ± 0.6* 1.1 ± 0.6 1.2 ± 0.7 <0.001
Fasting free fattyacids (FFA) (mmol L)1)a 0.53 ± 0.21 0.55 ± 0.22 0.54 ± 0.27 0.53 ± 0.22 0.528
ClampFFA (nmol L)1)a 60 ± 164* 48 ± 70 52 ± 81 58 ± 99 0.022
Fastingglucose (mmol L)1) 5.1 ± 0.5 5.0 ± 0.5* 5.1 ± 0.6 5.1 ± 0.6 0.008
Fasting insulin (pmol L)1)a 32 ± 25* 28 ± 17* 31 ± 19* 38 ± 22 <0.001
Alanineaminotransferase (U L)1)a 21.4 ± 12.8** 18.8 ± 12.4 20.2 ± 10.2 20.5 ± 10.6 0.016
Gamma-glutamyltransferase (U L)1)a 27.4 ± 23.0** 24.5 ± 24.7* 25.2 ± 16.4* 30.0 ± 25.4 <0.001
Plasmaadiponectin (mg L)1)a 9.2 ± 3.9*,*** 8.7 ± 3.9*,*** 7.9 ± 3.5 7.8 ± 3.5 <0.001
Valuesaremeans ± SD.aP-valuesbasedonstatisticalanalysesof log-normalizedvalues.
*P < 0.05vs.Q4, **P < 0.05vs.Q2and***P < 0.05vs.Q3and inposthocanalysis.
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tions in the coding area of the CD36 gene leading to
CD36 deficiency in platelets and monocytes are rare
in Caucasians [24, 28]. Another methodological
explanationcouldbeamatrixeffectas lowconcentra-
tions were mostly run undiluted in contrast to the
remaining samples. Whatever the cause of the distri-
bution of sCD36, the log-normal sCD36 population
exhibited higher sCD36 in participants with dis-
turbed glucose tolerance,with theMetSy andwith an
increased likelihood of fatty liver disease, in accor-
dancewithpreviousfindings [10–13,29].
Targeted over-expression of CD36 in the liver causes
liver fat accumulation in mice. In addition, diet-in-
duced obesity is associated with higher liver CD36
expression, liver fat accumulationanddyslipidaemia
[6]. Todate, there havebeen few studies onhuman li-
ver CD36. In liver biopsies from patients with nonal-
coholic fatty liverdisease (NAFLD), expressionof fatty
acid transporting proteins, including CD36, corre-
latedwith liver fat content, and it was concluded that
multiple genes related to lipid metabolism were in-
volved in liver steatosis [30]. In a very recent study by
Miquilena-Colina and co-workers [31], subjects with
fatty liver andchronichepatitisC virus infectionwere
shown to have increased CD36 expression in liver
and significant associations between hepatic CD36
expression and both insulin resistance and the de-
gree of liver steatosis. Circulating sCD36 is associ-
ated with indicators of liver function, such as ALT, in
insulin-resistant subjects with IGT or T2D but not in
subjectswith normal glucose homoeostasis [11], and
ithasbeenhypothesized thatsCD36maybeamarker
of NAFLD. Here, we find that sCD36 increases with
increased likelihood of fatty liver and, furthermore,
that this association between sCD36 and fatty liver
was significant even after corrections for several con-
founders. The fact that we also find that sCD36 is
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Fig. 1 Markers of insulin resis-
tance, carotid atherosclerosis
and fatty liver across quartiles of
sCD36. Percentage of the RISC
cohort (n = 1296) with either im-
paired glucose tolerance (IGT) or
impaired fasting glucose (IFG)
representing impaired glucose
regulation (panel a), or the
presence of the MetSy (panel b),
values of insulin sensitivity (M ⁄ I
in lmol min)1 kg FFM)1 (nmol
L)1))1) measured by the eugly-
caemic–hyperglycaemic clamp
(panel c), carotid IMT in mm (pa-
nel d), fatty liver index (panel e)
and liver fat percentage (panel f)
across quartiles (Q1–Q4) of
sCD36. Data are given as
mean ± SEM. Except for IGT ⁄
IFG, the P-values are based on
statistical analyses of log-nor-
malized values. aP<0.05 vs. Q2,
bP<0.05 vs. Q3 and cP<0.05 vs.
Q4inposthocanalysis.
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associated with LF% in the sCD36 log-normal popu-
lation and that the variables used for the estimation
of the LF% are different from those used for the FLI
supports thishypothesis.Onemajor limitationis that
the derived measure FLI was developed in a general
population using ultrasonography rather than MRS,
which is the gold-standard technique for the diagno-
sis of NAFLD. However, LF% has been validated by
MRS. As there is a strong correlation between the two
algorithms of fatty liver despite the fact that they are
derived fromdifferent variables, andbecause sCD36,
being a fatty acid transporter of the liver, is correlated
with both, it is reasonable to speculate that sCD36
maybeanewmarker of liver fat. Additional studies of
sCD36 and direct measures of liver fat, and ideally
also liver CD36 expression, would improve our
understanding of the involvement of CD36 in liver
steatosisand inflammation.
Numerous studies support the role of CD36 in foam
cell formation and the development of unstable ath-
erosclerotic plaques [3, 21, 32, 33]. CD36 expression
levels are tissue specific and regulated by a variety of
factors. Some of these factors are inter-related, such
as plasma lipids and insulin resistance as well as
inflammation, oxidative stress and insulin resis-
tance. Most factors that influence CD36 expression
also predispose to atherosclerosis. Previous studies
have indicated that the same factors influence both
plasmasCD36 level and tissueCD36expression.The
present finding of a positive relationship between
sCD36 and IMT in a large healthy nondiabetic popu-
lation indicates that sCD36 may be a marker of ath-
erosclerosis. The persistent relationship between
sCD36and IMTafter correction forconfounders such
as gender, age, glucose tolerance status, smoking
habits and alcohol consumption supports this
hypothesis, and although the correlation is weak, we
propose that sCD36has the potential to be an impor-
tant marker of atherosclerosis. Previous analysis of
theRISCcohort revealed that fasting insulinmaybea
stronger contributor to cardiometabolic risk andath-
erosclerosis than insulin sensitivity (M ⁄ I) in a healthy
population [34], andconsistentwith this,wefind that
fasting insulin is better correlated with sCD36 than
M ⁄ I.
In our study population, there were generally higher
levels ofMetSy risk factors inmen as expected froma
number of studies, and accordingly, sCD36 was
higher in men than in women. We have previously
found higher sCD36 levels in healthy men (A. Hand-
berg, unpublished data), but to our knowledge gen-
der-dependent expression of cell-bound CD36 has
not been investigated.Elevated sCD36maybe linked
to higher FLI and LF% in men, reflecting increased
levels of liver enzymes, BMI, waist circumference and
triglycerides and thus increased expression of liver
CD36. IMT was also greater in men indicating
increased atherosclerosis, which also potentially
contributes to the elevated plasma CD36. Thus, at
present, the cause of the observed sCD36 gender
difference isunclear.Amajor limitationof thepresent
study is that no data were available regarding CD36
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Fig.2 Distribution of sCD36 in thestudypopulations.Distri-
bution of log sCD36 amongst all study participants
(n = 1296; upper panel) and in the log-normal study popula-
tion (n = 1029; lower panel). The dashed line indicates the
mean level of log sCD36 ()0.38) at the lower end of the distri-
butionatwhich frequenciesstarts to increaseagain.
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expression in cells and tissues key to the develop-
mentof theMetSy, suchasvesselmacrophages, skel-
etalmuscle, liver, fat andmonocytes, to compare cir-
culating sCD36 with tissue CD36 expression. Such
studies should probably be conducted in an animal
model of theMetSyandonasmall scale.
In summary, the results of this studyshowthat in the
context of a cross-sectional study of healthy nondia-
betic subjects, sCD36 represents a new biomarker of
a phenotype of insulin resistance, carotid atheroscle-
rosisand fatty liver. Prospective studiesareneeded to
further evaluate the role of sCD36 as a marker of the
inter-relationship between atherosclerosis and fatty
liver in insulin resistance.
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